Mitoguazone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mitoguazone
Accession Number
DB12967
Type
Small Molecule
Groups
Investigational
Description

Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
OD5Q0L447W
CAS number
459-86-9
Weight
Average: 184.207
Monoisotopic: 184.118492418
Chemical Formula
C5H12N8
InChI Key
MXWHMTNPTTVWDM-VEPASKNESA-N
InChI
InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3?
IUPAC Name
N-{[(1E)-1-(carbamimidamidoimino)propan-2-ylidene]amino}guanidine
SMILES
CC(\C=N\NC(N)=N)=NNC(N)=N

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mitoguazone.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Mitoguazone.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Mitoguazone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitoguazone.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mitoguazone.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Mitoguazone.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mitoguazone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mitoguazone.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Mitoguazone.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitoguazone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoguazone.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Mitoguazone.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Mitoguazone.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Mitoguazone.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Mitoguazone.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Mitoguazone.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoguazone.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Mitoguazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Mitoguazone.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mitoguazone.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5351154
PubChem Substance
347829107
ChemSpider
34210109
ATC Codes
L01XX16 — Mitoguazone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3TerminatedTreatmentMalignant Lymphomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.313 mg/mLALOGPS
logP0.24ALOGPS
logP-1.2ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)17.98ChemAxon
pKa (Strongest Basic)9.06ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area148.52 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity90.67 m3·mol-1ChemAxon
Polarizability18.47 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as guanidines. These are compounds containing a guanidine moiety, with the general structure (R1R2N)(R3R4N)C=N-R5.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Guanidines
Direct Parent
Guanidines
Alternative Parents
Hydrocarbon derivatives
Substituents
Guanidine / Hydrocarbon derivative / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 19:38 / Updated on November 09, 2017 05:15